Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoid leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: Lymphoid leukemia. Displaying page 7 of 19.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2008-006342-25 Sponsor Protocol Number: HM08 / 8625 Start Date*: 2009-02-09
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or withou...
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000796-14 Sponsor Protocol Number: HM10/9652 Start Date*: 2011-12-01
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL
    Medical condition: Chronic Lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003593-13 Sponsor Protocol Number: HM17/102122 Start Date*: 2018-02-15
    Sponsor Name:University of Leeds
    Full Title: UK CLL Long-term Follow-up Study
    Medical condition: Chronic lymphocytic leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003608-11 Sponsor Protocol Number: RG_12-125 Start Date*: 2014-02-20
    Sponsor Name:University of Birmingham
    Full Title: IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.
    Medical condition: Chronic Lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10009310 CLL LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000569-35 Sponsor Protocol Number: CLL2-BIG Start Date*: 2014-12-29
    Sponsor Name:University of Cologne
    Full Title: A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA1...
    Medical condition: Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002752-33 Sponsor Protocol Number: NL.66760 Start Date*: 2019-01-17
    Sponsor Name:VU University Medical Center
    Full Title: A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell Tr...
    Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Non hodgkin lymphoma (any grade), Acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    20.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    20.0 100000004864 10009310 CLL LLT
    20.0 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003313-17 Sponsor Protocol Number: GS-US-312-0123 Start Date*: 2014-06-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lympho...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) BE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) ES (Completed) PL (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003778-15 Sponsor Protocol Number: 20130265 Start Date*: 2017-11-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)
    Medical condition: relapsed/refractory B-precursor Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    20.0 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004836-39 Sponsor Protocol Number: Initial-1 Start Date*: 2017-11-01
    Sponsor Name: Goethe Universität
    Full Title: An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy I...
    Medical condition: Acute lymphoblastic leukemia, Philadelphia-chromosome and BCR-ABL negative disease, patient aged 56 years or older
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001754-18 Sponsor Protocol Number: CLR_15_03 Start Date*: 2017-06-07
    Sponsor Name:Sun Pharma Advanced Research Company Ltd.
    Full Title: A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myel...
    Medical condition: Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    19.1 100000004864 10009015 Chronic myeloid leukemia LLT
    19.1 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Prematurely Ended) ES (Ongoing) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-005159-14 Sponsor Protocol Number: GC P#02.01.001 Start Date*: 2008-04-15
    Sponsor Name:Gamida Cell-Teva Joint Venture Ltd.
    Full Title: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in ...
    Medical condition: High-risk haematological malignancies (including AML, ALL, CML, NHL, HD, and MDS) with an indication for allogeneic haematopoietic stem cell transplantation, to support haematopoietic reconstitutio...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10009015 Chronic myeloid leukemia LLT
    9.1 10001690 ALL LLT
    9.1 10028533 Myelodysplastic syndrome LLT
    9.1 10020206 Hodgkin's disease LLT
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001866-90 Sponsor Protocol Number: AALL1131 Start Date*: 2014-07-15
    Sponsor Name:Children's Oncology Group
    Full Title: Treatment of Patients for newly diagnoised High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine in the Very High Risk Stratum
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001173-41 Sponsor Protocol Number: CLO08808 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Corporation
    Full Title: An Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients with Acute Lymphobla...
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000766-30 Sponsor Protocol Number: HO146 Start Date*: 2018-03-09
    Sponsor Name:HOVON Foundation
    Full Title: Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. A phase II trial.
    Medical condition: Precursor B-acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001174-18 Sponsor Protocol Number: CLO21800205 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase I/II Dose-Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003466-13 Sponsor Protocol Number: GMALL082013 Start Date*: 2015-09-15
    Sponsor Name:Goethe University Frankfurt
    Full Title: Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a ...
    Medical condition: Newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma Age 18 to 55 y
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065923 Lymphoblastic lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001561-27 Sponsor Protocol Number: 2000790 Start Date*: 2014-08-25
    Sponsor Name:VU university medical center
    Full Title: Vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia: comparing one-hour infusions with short-term infusions (the VINCA-study)
    Medical condition: Pediatric oncology, acute lymphoblastic leukemia, nephroblastoma, medulloblastoma, low-grade glioma, Hodgkin lymphoma, rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10001690 ALL LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023022-20 Sponsor Protocol Number: CLL2S Start Date*: 2011-08-03
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agen...
    Medical condition: CLL patients with thrombocytopenia and indication for chemotherapeutic treatment with alkylating agents and/or purine analogues
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    15.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022946-25 Sponsor Protocol Number: AALL0622 Start Date*: 2011-12-19
    Sponsor Name:Children's Oncology Group
    Full Title: Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)
    Medical condition: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    14.1 10022891 - Investigations 10034877 Philadelphia chromosome positive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004540-29 Sponsor Protocol Number: Pona-CELL Start Date*: 2020-10-06
    Sponsor Name:Ústav hematologie a krevní transfuze
    Full Title: Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia
    Medical condition: NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 21:51:45 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA